Welcome to our dedicated page for Clearside Biomedical news (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomedical stock.
Clearside Biomedical, Inc. (symbol: CLSD) is a prominent clinical biopharmaceutical company based in Alpharetta, Georgia. Specializing in the development of pharmacological therapies, the company's primary focus is on treating blinding diseases of the eye through their innovative suprachoroidal space (SCS) technology.
Clearside Biomedical's cornerstone is their SCS Microinjector®, a proprietary device that facilitates a non-surgical, office-based procedure. This technology allows for targeted delivery of therapies directly to the macula, retina, or choroid, which could potentially preserve and enhance vision for patients suffering from severe eye conditions.
One of the company's significant achievements is the robust safety profile and encouraging efficacy data from multiple studies using the SCS Microinjector®. These findings have been featured in numerous oral and poster presentations, highlighting the potential of Clearside’s technology in ophthalmic therapeutics.
Clearside Biomedical continues to advance its pipeline of ophthalmic therapies, collaborating with various partners to bring innovative treatments to market. The company remains committed to improving the quality of life for individuals with vision-threatening diseases through groundbreaking research and development.
Recent Achievements:
- Clinical data utilizing Clearside’s suprachoroidal delivery technology featured in multiple presentations.
- Enhanced safety and efficacy data presented, showcasing the utility of the SCS Microinjector®.
Investors and media can reach out to Jenny Kobin and Remy Bernarda for more information at ir@clearsidebio.com or by calling (678) 430-8206.
Clearside Biomedical (Nasdaq: CLSD) has announced the initiation of its ODYSSEY Phase 2b clinical trial for CLS-AX, a new treatment for wet age-related macular degeneration (AMD). With enrollment starting this quarter, the trial will evaluate 60 participants over 36 weeks in a randomized, double-masked format using CLS-AX and aflibercept as comparators. Topline results are anticipated in Q3 2024.
The ODYSSEY trial builds on data from the earlier OASIS trial, which indicated good tolerability and an excellent safety profile for CLS-AX. This study aims to potentially reduce treatment frequency while maintaining visual acuity in patients, addressing the treatment burden associated with existing therapies.
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company focused on innovative eye therapy delivery, will have its CEO George Lasezkay participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference. This event is scheduled for April 19, 2023, at 1:30 p.m. ET. A live and archived webcast will be available on Clearside's website for three months in the Investors section. Clearside specializes in delivering treatments to the back of the eye through the suprachoroidal space (SCS®) using its proprietary SCS Microinjector®. Its first product, XIPERE®, is already available in the U.S. for ocular conditions. The company partners strategically to leverage other ophthalmic innovations.
Clearside Biomedical (NASDAQ:CLSD) has appointed Arshad M. Khanani, M.D., and Lejla Vajzovic, M.D., to its Scientific Advisory Board (SAB), enhancing its expertise in retinal therapies. Dr. Khanani is a leader in clinical research with over 100 clinical trials to his name, while Dr. Vajzovic specializes in vitreoretinal diseases and innovative surgical techniques. The SAB, led by Thomas A. Ciulla, M.D., will provide insights into Clearside's CLS-AX program for wet AMD and the suprachoroidal delivery of therapies. The company is committed to improving vision for patients with sight-threatening conditions through its proprietary SCS Microinjector technology.
Clearside Biomedical (Nasdaq: CLSD) announced the initiation of the Phase 2b ODYSSEY Trial for CLS-AX targeting wet AMD, with enrollment expected to commence in Q2 2023. The company highlighted favorable safety data from its OASIS Phase 1/2a trial, showing 67% of participants remained treatment-free for at least six months. Financially, Clearside reported a significant decline in revenues, with Q4 2022 revenue at $330,000, down from $25.7 million in Q4 2021, primarily due to a one-time milestone payment the previous year. The net loss for the year reached $32.9 million, or $0.55 per share, compared to a net income of $376,000 in 2021.
Clearside Biomedical, Inc. (Nasdaq: CLSD) will report its Q4 and full-year 2022 financial results on March 9, 2023, after market close. A webcast and conference call will follow at 4:30 p.m. ET. This session will provide insights into the company’s financial performance and corporate updates. Clearside specializes in innovative drug delivery methods to the back of the eye, primarily through its SCS Microinjector platform, enhancing treatments for eye diseases. The company’s first product, XIPERE, is available in the U.S. Further details can be found on their website.
Clearside Biomedical, Inc. (Nasdaq: CLSD) presented favorable safety and efficacy data for its CLS-AX therapy during two significant medical conferences in February 2023. The OASIS clinical trial demonstrated that 67% of participants went at least six months without needing additional treatment, with a treatment burden reduction of 77-85%. The data confirmed a strong safety profile at all tested doses. Additionally, advances using the proprietary SCS Microinjector were highlighted for treating various eye conditions. The company plans to initiate the Phase 2b ODYSSEY clinical trial soon.
Clearside Biomedical (NASDAQ:CLSD) announced the upcoming presentation of data from its OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) at two medical meetings in February 2023. The trial investigates the safety and tolerability of CLS-AX in wet AMD patients unresponsive to anti-VEGF therapy. Key presentations include:
- Angiogenesis, Exudation, and Degeneration 2023: Feb 11, 2023, by Mark R. Barakat, M.D.
- The Macula Society 46th Annual Meeting: Feb 18, 2023, by Baruch D. Kuppermann.
CLS-AX aims to improve treatment efficacy through direct targeting in the suprachoroidal space.
Clearside Biomedical, Inc. (NASDAQ:CLSD) announced the transition of Chief Medical Officer Thomas A. Ciulla, M.D., M.B.A., to Chief Medical Advisor-Retina, effective February 17, 2023. Dr. Ciulla will continue to provide expertise as chair of the Scientific Advisory Board and support the ODYSSEY Phase 2b clinical trial. CEO George Lasezkay highlighted Dr. Ciulla's contributions to the company’s success, particularly in advancing their suprachoroidal delivery platform. The clinical team, led by Chief Clinical Officer Dr. Susan Coultas, is prepared to initiate the ODYSSEY trial, showcasing Clearside's commitment to innovative eye therapies.
Clearside Biomedical, Inc. (Nasdaq: CLSD) announced positive outcomes from the Extension Study of its OASIS Phase 1/2a clinical trial for CLS-AX, a treatment for wet AMD. Key findings show that 67% of study participants went at least six months without additional treatments, experiencing a 77-85% reduction in treatment burden. CLS-AX demonstrated a favorable safety profile with no serious adverse events reported. The upcoming ODYSSEY Phase 2b trial is expected to commence in Q1 2023, aiming to further evaluate CLS-AX's efficacy compared to existing therapies. As of December 31, 2022, Clearside’s cash and cash equivalents stood at approximately $48.3 million.
Clearside Biomedical (NASDAQ:CLSD) has announced its participation in several key conferences this November and December 2022. The events include:
- BTIG Ophthalmology Day on November 29 at 10:30 a.m. ET
- Piper Sandler 34th Annual Healthcare Conference on December 1 at 9:50 a.m. ET
- Ophthalmology Innovation Summit on December 3
- Cantor MedTech Conference on December 8 at 2:45 p.m. ET
Webcasts will be available on the Clearside website under the Investors section, showcasing the company's innovative SCS Microinjector platform for targeted eye therapy delivery.
FAQ
What is the current stock price of Clearside Biomedical (CLSD)?
What is the market cap of Clearside Biomedical (CLSD)?
What does Clearside Biomedical, Inc. specialize in?
Where is Clearside Biomedical, Inc. located?
What is the SCS Microinjector®?
How does Clearside Biomedical's technology benefit patients?
What recent achievements has Clearside Biomedical reported?
Who can be contacted for investor and media inquiries?
What kind of presentations feature Clearside's technology?
What diseases is Clearside Biomedical targeting with their therapies?
Is Clearside Biomedical's procedure surgical?
What is the significance of Clearside's technology in ophthalmology?
